Le Lézard
Classified in: Health
Subjects: POL, AVO

Catholics for Choice: Trump Administration Attacks Title X Funding, Threatening Healthcare Access for Millions of Americans


WASHINGTON, Aug. 15, 2019 /PRNewswire-PRWeb/ -- Jon O'Brien, president of Catholics for Choice, issued the following statement:

"The deadline for family planning clinics to provide written assurance that they will comply with the Trump Administration's domestic gag rule is next Monday, August 19. Similar to the Global Gag Rule, the new policy restricts providers and clinics that receive federal Title X funds. Clinics receiving family planning grants to provide contraception, STD tests and other much-needed services to low-income patients will have to stop providing abortion referrals or lose their funding.

Without relief from the courts, family planning clinics that choose to meet the needs of their patients rather than abide by the gag rule will be forced out of the Title X program. Cheating millions of vulnerable Americans of the ability to exercise their conscience and access birth control and other reproductive health services is unconscionable.

Catholics for Choice calls on Americans who support affordable reproductive healthcare to contact their members of Congress to protect Title X and safeguard access to birth control regardless of one's means."

 

SOURCE Catholics for Choice


These press releases may also interest you

at 04:58
Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the use of high-speed atomic force microscopy helps to understand the crucial role played by certain biomolecules in DNA wrapping dynamics. In...

at 04:00
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...



News published on and distributed by: